Password Reset

Fintech
Benzinga BioTech
Investment News
Stocks to Watch
Finance
Most Popular News Articles
Bitcoin News
Cramers Picks
Technology News
Stocks and Commodities
Daily Technical Analysis
CGC
Featured Stock
Emerging Markets
Economy
Investing
Options
Real Estate News
Nasdaq Stock News
Latest Articles in Real Estate
Mstardom Finance
Food and Drug Administration--Press Releases
What's New: Drugs RSS Feed
OTC Markets Group - News, Filings & Corporate Actions
ECB - European Central Bank
FRB: Press Release - All Releases
Press Releases
St. Louis Fed - Recent Research
Research Announcements – St. Louis Fed Economic Research
Economic Education
Investor Alerts and Bulletins
SEC.gov Updates: Litigation Releases
SEC.gov Updates: Proposed Rules

KoreSummit Miami Will Discuss Investor Relations and the Marketing of STOs

16 February 2019 - PRNewswire

MIAMI, Feb. 15, 2019 /PRNewswire/ -- In the final countdown for ...

The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings

15 February 2019 - Shanthi Rexaline

Biotech stocks got some reprieve in this week amid the release of earnings, clinical trial results presentations and positive FDA actions.

Among the noteworthy developments of the week:

The FDA panel ruling in favor of Johnson & Johnson (NYSE: JNJ)'s investigational therapy for treatment-resistant depression; The agency's approval of Novartis AG (NYSE: NVS)'s liver fluke infestation drug Egaten and a split-dosing regimen of J&J unit Janssen's Darzalex for multiple myeloma; Gilead Sciences, Inc. (NASDAQ: GILD)'s NASH candidate flunking a late-stage study.

Here are some key developments that a biotech investor should focus on next week.

Conferences 11th International Conference on Vascular Dementia – Feb. 15-16, in Amsterdam, Netherlands Amsterdam, Netherlands 30th European Heart Diseases and Heart Failure Congress – Feb. 18-19, in Amsterdam, Netherlands 14th Annual Conference on Nephrology & Renal Care – Feb. 18-19, in Singapore City, Singapore World Congress on Pain Medicine and Management – Feb. 20-21, in Singapore City International Meeting on Dermato Oncology – Feb. 20-21, in Dallas, U.S. 27th Annual Congress on Cancer Science and Targeted Therapies – Feb. 20-21, ...

Full story available on Benzinga.com

What is the Difference Between Magna Cum Laude and Summa Cum Laude?

17 February 2019 - Greg Daugherty

Cum laude" is a Latin term that translates to “with honor”. "Magna cum laude" means “with great honor,” and "summa cum laude" means “with greatest honor."

Stocks to Watch: DuPont, Nike, KB Home are stocks to watch

27 June 2014

Among the companies whose shares are expected to see active trade in Friday’s session are DuPont, Nike, and KB Home.

William Lyon Homes (WLH) CEO Matt Zaist on Q4 2018 Results - Earnings Call Transcript

17 February 2019

Washington Prime Group: Top Preferred Stock Pick With 10% Yield, 40% Upside

16 February 2019

How to Outwit Blockchain Analysis and Conceal Your Coins

17 February 2019 - Kai Sedgwick

How to Outwit Blockchain Analysis and Conceal Your Coins How do you convert bitcoin that’s associated with your identity into coins with no connection to your name? In an era of enhanced blockchain forensics tools, passing your coins through a few addresses and hoping for the best won’t cut it. Reclaiming your right to privacy and to own bitcoin anonymously calls for a smarter […]

The post How to Outwit Blockchain Analysis and Conceal Your Coins appeared first on Bitcoin News.

Long-Term Growth Stocks - Cramer's Mad Money (12/11/18)

12 December 2018

Don Cheadle stood up for trans kids on 'SNL' and the internet took notice

17 February 2019 - Adam Rosenberg

Don Cheadle, acclaimed actor and true-blue mensch.

The man behind Marvel's War Machine mask brought his politics to the Saturday Night Live stage on Feb. 16. He used fashion to make a statement, at one point introducing Gary Clark, Jr., the night's musical guest, while wearing a simple t-shirt adorned with the words "PROTECT TRANS KIDS."

It was a well-received fashion choice, to say the least.

shit like this is why he survived Infinity War pic.twitter.com/kvBDXQ6NXC

— tweeter valentine (@MamoudouNDiaye) February 17, 2019

Sunday morning Twitter is flooded with support for Cheadle under the #ProtectTransKids hashtag. Read more...

More about Entertainment, Tv, Saturday Night Live, Don Cheadle, and Entertainment

Gold Short Idea-Opinion

17 February 2019

Hi there ! This is a short idea-position for GC1!. As we see at the weekly chart the price of yellow metal reached the upper bollinger and a rebounce to median is expected rather than a huge breakout. Short term gold price might go further up to 1340$-1360$ and then the rebounce is high possible to 1280$. Dont forget that Gold is highly correllated to EURUSD. Indicators also sing a possible swing at prices of gold because RSI at overbought level above 50-60 and ADX will swing until the -DI crosses above the +DI. Hope you found this view helpfull. Invest with safety !

Bitcoin Struggles At The 50 EMA, Here's What We Know! (BTC)

15 February 2019

Hi friends! Welcome to this update analysis on Bitcoin! Today, we will be assessing the progression of the similarities of Bitcoin's current price action, compared to the bottoming formation that was produced in the bear market of 2015. So, without further ado, let's get right to it! Looking at the daily BTC chart, we can see that Bitcoin is having a difficult time rising above the 50 EMA (in orange.) This is quite concerning, as far as short term price action is concerned, because when compared to this point in 2015, price had rallied sharply above the 50 EMA. Unfortunately, since I am traveling and posting from my cellphone, I can't post a side-by-side comparison chart. However, you can view my previous comparison analysis, attached below, for reference. So yeah, Bitcoin is struggling to rally above the 50 EMA. Adding to the slight divergences from the 2015 bottoming formation, we can see that the triangle is extending further than before. If you'll notice, I've actually adjusted the bottom trendline of the triangle from the dashed black trendline, to the solid black trendline at the bottom. I've done this because I'm a bit torn, now that Bitcoin is struggling to rally above the 50. Technically, you can see that where the triangle was originally drawn (black dashed trendline) price has fallen back below it. So, price could continue to trend sideways to lower, but stay inside of this extended version of the triangle, until it actually rises above the 50 EMA. Let's not forget though, we ARE analysts! We know that the 50 EMA has been powerful resistance, and Bitcoin is continuing to struggle at it. That is not a positive sign. At the same time, a bottoming fractal that matches 2015's bottom has been printed, but we're starting to see some possible deviations from that. So, until price can rally above the 50 EMA my short term view is neutral. On the MACD, we can see that it is now approaching the zero line. Momentum is slowing down, but it is still currently rising to the upside. On the RSI, we can see that strength was recently rejected at a multi-month resistance level (red horizontal trendline.) Each time that happened, a fall in price occurred next. So, based on that, and the failure at the 50 EMA, there are some reasons to be cautious here. Overall, there are mixed signals in BTC right now. We may have bottomed already, but indicators are still showing mixed data. Until price can rally above the 50 EMA, providing further confirmation of the 2015 bottoming fractal, I will remain cautiously optimistic that the bottom is in. That's my view, but it's always best to do your own homework. Good luck trading, everyone! I'm the master of the charts, the professor, the legend, the king, and I go by the name of Magic! Au revoir. ***This information is not a recommendation to buy or sell. It is to be used for educational purposes only.*** -JD-

CGC - Ascending Channel

15 February 2019

The uptrending channel in CGC gives us a confidence band that the price action is likely to stay within until the trend eventually changes. So far, every test of trendline support on the way up has provided CGC bulls with a low-risk, high-reward buying opportunity for shares. In other words, it could be a "buy the dips” stock. The current resistance level is around $52, a jump of ~8% from its current price around $48. However, should share rise above that resistance level, the stock will climb even higher and above the previous highs of $59.25

$aapl pop to 176 coming short term

17 February 2019

I am eyeing a 5/10 ema crossing about to happen on weekly timeframe. This cross targets the 20 ema on weekly.

Canopy Growth Corporation (CGC) Reports Q3 Loss, Misses Revenue Estimates

16 February 2019

Canopy Growth Corporation CGC came out with a quarterly loss of 0 67 per share versus the Zacks Consensus Estimate of a loss of 0 15 This compares to loss of 0 11 per share a year ago These figures are adjusted for non recurring items This quarterly report represents an earnings surprise

Wall Street points to higher open; Dow futures jump 200 points

22 February 2016

Investing.com Investing.com U.S. stock markets pointed to strong gains at the open on Monday, with the Dow futures briefly jumping more than 200 points as a rebound in oil prices boosted market sentiment. The blue chip Dow futures climbed

The Data is Already Out There to Design Better Markets

15 February 2019

Data collection is no justification for increasing investor

Canopy Growth Corporation (CGC) Reports Q3 Loss, Misses Revenue Estimates

16 February 2019

Dow Grabs 8th Straight Weekly Win on Trade-Deal Hopes

15 February 2019

The Dow rallied today for a huge win thanks to hopes that U S China trade talks are on the right course Wall Street was undisturbed by President Donald Trump declaring a national emergency to gain funds for a border wall as the Nasdaq and S amp P 500 rose as well Bank stocks were

Social Security's Woes May Make Your Golden Years Less Lustrous

16 February 2019

Six decades ago one of the most iconic phrases was born the golden years It was a term coined to describe the advanced years of a person s lifetime and was meant to convey the joy that could be had during those years You see during the 1950s Social Security provided a

U.S. Home Sales are Plummeting And Nobody's Sure Why

30 January 2019

The U.S. housing market is crumbling--a worrying indication that an economic catastrophe could be brewing. Yet, nobody seems sure why this is happening in an economy that remains hale and hearty by most measures. But don’t rush to your banker just yet hoping to get an easy deal. Rejections for mortgages and

COURT ORDERS $1 BILLION JUDGMENT AGAINST OPERATORS OF WOODBRIDGE PONZI SCHEME TARGETING RETAIL INVESTORS

15 February 2019 - Glenford Robinson

"This resolution accomplishes one of the SEC's core missions to protect retail investors," said Stephanie Avakian, Co-Director of the SEC's Division of Enforcement. "Mr. Shapiro and other defendants will be held accountable and required to pay substantial penalties for their misconduct." "Our complaint charged that when Woodbridge's fictitious business model collapsed, the company stopped paying investors and filed for Chapter 11 bankruptcy protection," said Eric I. Bustillo, Director of the SEC's Miami Regional Office. "The settlement provides for the return of significant funds to investors."

Statement from FDA Commissioner Scott Gottlieb, M.D., on new policy to improve access and foster price competition for drugs that face inadequate generic competition

15 February 2019

FDA announces new draft guidance titled, Competitive Generic Therapies, to help provide even greater clarity to industry about the CGT pathway.

Additions/Deletions for Prescription and OTC Drug Product Lists

15 February 2019

The list has been updated through December 2017.

Trinity Capital Corporation (TRIN: OTCQX U.S. Premier) | Rigrodsky & Long, P.A. Files Class Action Suit Against Trinity Capital Corporation

16 February 2019

Benoît Cœuré: The euro’s global role in a changing world: a monetary policy perspective

15 February 2019

Agencies extend comment period on proposed standardized approach for calculating the exposure amount of derivative contracts

15 February 2019

Agencies extend comment period on proposed standardized approach for calculating the exposure amount of derivative contracts

SEC Files Charges in Elaborate Microcap Stock Fraud

15 February 2019

The Securities and Exchange Commission today announced charges against four individuals and related businesses for their roles in two microcap frauds and unlawful securities offerings. In sum, the alleged illegal transactions resulted in proceeds of more than $25 million.

According to the SEC’s complaint, from approximately December 2012 to June 2013, microcap stock financier Magna Group, which was founded and owned by Joshua Sason, engaged in a scheme to acquire fake convertible promissory notes supposedly issued by penny stock issuer Lustros Inc. and then to convert those notes into shares of Lustros common stock. The defendants then sold the shares to unsuspecting retail investors, who did not know that the shares were fraudulently acquired and were being sold illegally. The defendants’ sales of the Lustros shares also had the effect of destroying the value of the Lustros shares held by the public. The complaint alleges that Marc Manuel, Magna Group’s former head of research and due diligence, personally negotiated and executed the sham transactions.

The complaint also alleges that in November 2013, Magna Equities II, which also was wholly-owned by Sason, and Manuel, purchased another fake promissory note from Pallas Holdings. Magna Equities II and the note’s issuer, NewLead Holdings Ltd., later agreed to retire the fake debt in exchange for shares of the issuer through a court-approved settlement agreement. To obtain approval of the settlement, Sason and Magna Equities II falsely swore to the court that the fake promissory note was a bona fide debt of NewLead. Kautilya “Tony” Sharma and Perian Salviola, who controlled Pallas Holdings, are alleged to also have participated in the scheme.

“As alleged in our complaint, Magna Group and its co-defendants used fake debt instruments to unlawfully obtain shares in microcap companies, which they then dumped on unsuspecting retail investors,” said Sanjay Wadhwa, Senior Associate Director of the SEC’s New York Regional Office. “This action demonstrates the resolve of the SEC in pursuing fraudsters who use elaborate financing schemes to engage in securities fraud.”

The SEC’s investigation was conducted by Lee A. Greenwood, Philip A. Fortino, John O. Enright, Christopher Ferrante, Diego Brucculeri, and Sheldon L. Pollock of the New York office. The SEC’s litigation will be handled by Messrs. Fortino, Greenwood, Enright, and Alexander M. Vasilescu. The case is being supervised by Mr. Wadhwa.

Gauging Market Responses to Monetary Policy Communication

14 February 2019

By Kevin L. Kliesen, Brian Levine, Christopher J. Waller in Review.

Chinese Royalties

8 February 2019

Read up on what China pays to use U.S. intellectual property.

2019 AP Economics Conference

12 July 2019

Are you a seasoned AP economics instructor, new to teaching AP econ courses, or simply contemplating teaching them? If so, join us as Federal Reserve economists, AP economics exam readers, exam developers and instructors, and St. Louis Fed economic education staff present a program packed with the information you need to be successful.

Investor Bulletin: 10 Investment Tips for 2019

12 February 2019

Whether you are a first-time investor or have been investing for years, here are 10 tips from the SEC’s Office of Investor Education and Advocacy to help you in 2019.

Brian Hirsch et al.

15 February 2019

Settlement Concluded with Broker in Case Alleging Public Offering Allocation Fraudulent Practices

Extension of Comment Period for Updated Disclosure Requirements and Summary Prospectus for Variable Annuity and Variable Life Insurance Contracts

14 February 2019

COURT ORDERS $1 BILLION JUDGMENT AGAINST OPERATORS OF WOODBRIDGE PONZI SCHEME TARGETING RETAIL INVESTORS

“This resolution accomplishes one of the SEC’s core missions to protect retail investors,” said Stephanie Avakian, Co-Director of the SEC’s Division of Enforcement. “Mr. Shapiro and other defendants will be held accountable and required to pay substantial penalties for their misconduct.”

“Our complaint charged that when Woodbridge’s fictitious business model collapsed, the company stopped paying investors and filed for Chapter 11 bankruptcy protection,” said Eric I. Bustillo, Director of the SEC’s Miami Regional Office. “The settlement provides for the return of significant funds to investors.”

SEC Charges Cognizant and Two Former Executives With FCPA Violations

“Bribery to further corporate goals is an illusory path to long-term success. While always the wrong choice, it is particularly egregious when senior executives chart that course for those they lead, as our complaint alleges here. We are committed to holding them accountable for their actions,” said Charles E. Cain, Chief of the SEC Enforcement Division’s FCPA Unit.

FDA Authorizes First Interoperable Insulin Pump Intended to Allow Patients to Customize Treatment Through their Individual Diabetes Management Devices

“Diabetes is a complicated disease that requires close monitoring and carefully tailored treatments. We’ve heard from the patient community that having the ability to customize their own diabetes management devices is important to them. Advances in digital health make more tailored approaches to diabetes care possible,” said FDA Commissioner Scott Gottlieb, M.D. “The marketing authorization of the first ACE insulin pump intended for interoperable use has the potential to aid patients who seek more individualized diabetes therapy systems and opens the door for developers of future connected diabetes devices to get other safe and effective products to patients more efficiently. Because the FDA’s action creates a new regulatory classification, future ACE insulin pumps will be able to go through the more efficient 510(k) review process, helping to advance this innovative technology. We’re committed to advancing new ways to accelerate the development of innovations that can improve patient care while strengthening our pre- and post-market tools for determining the safety and effectiveness of these new technologies.

FDA Warns Patients and Doctors About Recall of Home-use Test Strips Used with Device to Monitor Blood Thinner Warfarin, Not Authorized for Sale in U.S.

“Monitoring warfarin dosing is a critical part of using the drug properly to prevent and treat blood clots. Using faulty strips can lead to errors in medication dosage that could cause serious harm or death in some patients. That’s why it’s so concerning that this distributor continued to sell these test strips in the U.S. even though domestic sales had been stopped due to safety concerns. To reduce risks to patients, we’re warning health care providers and the public about the dangers associated with this product,” said FDA Commissioner Scott Gottlieb, M.D. “Distributing products that are not labeled or authorized for sale in the United States raises significant concerns for us in view of the serious safety issues with these test strip devices, and our work on this matter is not finished. Our top priority is the immediate safety of patients, and we’re taking steps to ensure the products that this company distributed are removed from the market.”

SEC Charges Four Public Companies With Longstanding ICFR Failures

According to the SEC’s orders, year after year, the four companies disclosed material weaknesses in ICFR involving certain high-risk areas of their financial statement presentation. As discussed in the SEC orders, each of the four companies took months, or years, to remediate their material weaknesses after being contacted by the SEC staff. One of the companies is still in the process of remediating its material weaknesses.

Mstardom Finance Empowering the Investing and Trading Community!

Password Reset

Like this:

Password Reset

Share:

Like this: